1- Introduction

In the past decades, diverse therapeutic approaches have been developed to specifically counteract the immune-suppressive mechanisms within the tumor microenvironment (TME), with the development of immune checkpoint inhibitors (ICIs) reaching a revolutionary milestone in the field of immuno-oncology. Most notably, ICIs targeting CTLA-4 or PD-L1/PD-1 have yielded remarkable clinical responses for a variety of cancer types, with a range of drugs currently approved targeting these axes available as cancer treatments ¹.

However, despite the introduction of these promising ICIs some cancer types do not effectively respond ^2–5. Therefore, identifying novel immune-checkpoints are urgently needed for ovarian cancer. Besides from the recently identified immune-checkpoints LAG-3, TIM-3, TIGIT, VISTA and many others ^6–9. One particular, less established immune-checkpoint is the protein GPR56. GPR56 is an adhesion G-protein-coupled receptor with an array of functions, ranging from cortical development ^10,11, anti-depressant response ¹², hematopoietic development ¹³, to tumor cell adhesion and progression ^14,15.

GPR56 expression and function have not been evaluated in the context of tumor infiltrating lymphocytes (TILs) yet. As the magnitude, composition, quality, and phenotypic features of the TIL population have been linked to treatment response-rates and outcome ¹⁶, we here identified that GPR56 is expressed on TILs and investigated its role as a potential immune checkpoint within the context of cancer.

2- GPR56 might be a potential novel immunotherapeutic target for reactivation of tumor-infiltrating and tumor-reactive lymphocytes.

In this study (10.3390/cancers14133164), we set out to identify GPR56 expression on TIL fractions from various tumor types and to subsequently phenotypically define these populations by consulting RNA sequencing datasets.

Within a single-cell tumor immune transcriptomic (scRNAseq) dataset covering different tumor types, GPR56 mRNA expression was detected in various tumor-infiltrating immune cell sub-types, especially the expression was high within the cytotoxic and terminally exhausted CD8 T cells subsets. Analysis of the differentially expressed genes (DEGs) of the GPR56-positive and GPR56- negative cytotoxic CD8 T cells and terminally exhausted CD8 T cells revealed that GPR56-positive population presented significantly higher expression of genes associated with cytotoxic/(pre-)exhausted/tumor-reactive gene signatures. Further, GPR56 expression levels, as well as expression of several effector/co-stimulatory molecules identified in the sequencing analysis, were confirmed on TILs from epithelial ovarian cancer (EOC) patients.

GPR56 was subsequently evaluated on healthy primary human T cells and was compared with TILs isolated from EOC patients. This revealed higher expression levels of GPR56 on the total CD3 population (4% vs. 15%) as well as on the CD4 (1% vs. 15%) and CD8 (8% vs. 11%) fractions of TILs compared to healthy primary human T cells, although clear patient variability was observed. Further, Upon MHC-independent activation of TCR signaling by anti-CD3 single-chain antibody fragment-expressing ES-2 cells (ES-2scFvCD3), GPR56-expressing TILs upregulated GPR56 expression by approximately three-fold (CD3, 5% to 15%; CD4, 6% to 16%; CD8, 3% to 12%). Such an increase was not detected on TCR-stimulated healthy primary human T cells.

MHC-independent activation of TCR signaling was also subsequently induced by ES-2scFvCD3 or FADUscFvCD3 cells in T cell line Jurkat ectopically expressing GPR56 (Jurkat.GPR56). This revealed a significantly stronger upregulation of activation markers CD25 and CD69 on Jurkat.GPR56 compared to wild type Jurkat (Jurkat.WT) or control Jurkat cells (Jurkat.EV).

Furthermore, we ectopically expressed GPR56 on primary healthy T cells and assessed the migration potential of those cells in response to chemoattractants. T cells. A reduced migratory potential towards chemoattractant SDF-1 (CXCL12) was subsequently observed for primary healthy T cells ectopically expressing GPR56 compared to empty vector-transduced primary healthy T cells. Thus, GPR56 expression on primary healthy T cells affects in vitro migration in response to chemoattractant SDF-1.

Interestingly, Upon the subsequent co-culture of GPR56-expressing Jurkat.NFAT-luc reporter cells with ES2-anti-CD3 cells, both GPR56-expressing and control Jurkat.NFAT-luc cells increased luminescence levels compared to the Jurkat.NFAT-luc cells alone. However, a significant decrease in luminescence was detected for Jurkat.NFAT-luc cells expressing GPR56 compared to control cells. Thus, GPR56 inhibited T cell activation in the Jurkat.NFAT-luc model system.

Highlights of the study (10.3390/cancers14133164)

1. GPR56 Is Expressed in Cytotoxic and Terminally Exhausted CD8 TILs That Display a Tumor-Reactive Phenotype across Multiple Tumor Types
2. GPR56 Expression Is Elevated on Ovarian Cancer TILs Compared to Healthy Peripheral Blood Lymphocytes and Associates with an Effector Memory Phenotype
3. TCR Stimulation Upregulates GPR56 Expression on TILs and Enhances the Activation Status of T Cells
4. Ectopic GPR56 Expression Inhibits Migration of Primary Healthy T Cells

3- Conclusion

We identified that GPR56 is expressed on tumor infiltrating lymphocytes (TILs) and investigated its role as a potential immune checkpoint within the context of cancer. Based on our data, GPR56 indeed appears to function as an immune checkpoint in TILs and may thus provide a novel immunotherapeutic target for the reactivation of tumor-infiltrating and tumor-reactive lymphocytes.

References

1. Rotte, A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J. Exp. Clin. Cancer Res. 38, (2019).

2. Disis, M. L. et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity. https://doi.org/10.1200/JCO.2016.34.15_suppl.5533 34, 5533–5533 (2016).

3. Hamanishi, J. et al. Safety and antitumor activity of Anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. (2015) doi:10.1200/JCO.2015.62.3397.

4. Hodi, F. S. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. U. S. A. 100, 4712–4717 (2003).

5. Matulonis, U. A. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 30, 1080–1087 (2019).

6. Keane, C. et al. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Adv. 4, 1367–1377 (2020).

7. He, Y. et al. TIM-3, a promising target for cancer immunotherapy. Onco. Targets. Ther. 11, 7005 (2018).

8. Stamm, H. et al. Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. Oncoimmunology 8, (2019).

9. Zong, L. et al. Expression of the immune checkpoint VISTA in breast cancer. Cancer Immunol. Immunother. 69, 1437–1446 (2020).

10. Bae, B. Il et al. Evolutionarily dynamic alternative splicing of GPR56 regulates regional cerebral cortical patterning. Science 343, 764–768 (2014).

11. Li, S. et al. GPR56 Regulates Pial Basement Membrane Integrity and Cortical Lamination. J. Neurosci. 28, 5817 (2008).

12. Belzeaux, R. et al. GPR56/ADGRG1 is associated with response to antidepressant treatment. Nat. Commun. 11, (2020).

13. Maglitto, A. et al. Unexpected redundancy of Gpr56 and Gpr97 during hematopoietic cell development and differentiation. Blood Adv. 5, 829–842 (2021).

14. Huang, Y., Fan, J., Yang, J. & Zhu, G. Z. Characterization of GPR56 protein and its suppressed expression in human pancreatic cancer cells. Mol. Cell. Biochem. 308, 133–139 (2008).

15. Shashidhar, S. et al. GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion. Oncogene (2005) doi:10.1038/sj.onc.1208395.

16. Paijens, S. T., Vledder, A., de Bruyn, M. & Nijman, H. W. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell. Mol. Immunol. 18, 842–859 (2021).